share_log

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $84 Price Target

Benzinga ·  Apr 9 12:07

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $84 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 346

Recommended

Write a comment